Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera

• 主要な著者: Aaron T Gerds (著者), Claudia Castro (著者), Frank Snopek (著者), Megan M Flynn (著者), Alexandra G Ellis (著者), Meredith Mannin (著者), Ray Urbanski (著者)
• フォーマット: 図書
• 出版事項: Becaris Publishing Limited, 2023-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Aim: Patients with polycythemia vera (PV), a rare and chronic blood cancer, are at a higher risk for thromboembolic events, progression to myelofibrosis, and leukemic transformation. In 2021, ropeginterferon alfa-2b-njft (BESREMi R ) was approved in the US to treat adults with PV. The purpose of thi...